Slide 1: Exchange cover letter: press release submission
Corporate Office: Registered Office: Star 1, Opp IIM Bangalore, Bilekahalli, Cyber One, Unit No. 902, Sector 30A Bannergha a Road, Bengaluru – Plot No - 4 & 6, Vashi, Navi Mumbai 560076, India 400703 India T: +91 80 6784 0738 F: +91 22 2789 2924 T: 91 22 2789 2942 Date: January 23, 2026 BSE Limited Nati
Slide 2: OneSource Q3FY26 Results; Transitional Quarter – Revenue Deferred
Press Release January 23, 2026 OneSource Q3FY26 Results; Transitional Quarter – Revenue Deferred Pending Customer Approvals for Semaglutide in Canada Q3FY26 Performance Highlights • Revenues at ₹2,903 million, down 26% YoY, impacted by delayed semaglutide approvals in Canada • EBITDA at ₹173 million
Slide 3: About OneSource Specialty Pharma Limited
Press Release January 23, 2026 About OneSource Specialty Pharma Limited OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug
Slide 4: Investor Presentation Q3FY26
Investor Presentation | Q3FY26 January 23rd, 2026
Slide 5: Safe Harbor Statement
Safe Harbor Statement Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "i
Slide 6: Financial Performance and Business Outlook
Financial Performance and Business Outlook Q3FY26
Slide 7: Q3FY26 Performance Snapshot
Customer approval delays weigh on Q3FY26 performance; Inherent business strength intact, FY28 guidance reaffirmed ( Q3FY26 Performance Snapshot ) ₹2,903m Revenue As previously anticipated, this has been a subdued quarter due to $33.1m 26% YoY delays in customer approvals in Canada that have prolonge
Slide 8: Q3FY26 revenue shortfall resulted in unfavourable operating leverage
Q3FY26 revenue shortfall resulted in unfavourable operating leverage In $ m Q3FY26 Q2FY26 Q3FY25 YoY Key Updates Revenue 33.1 42.9 44.8 (26%) • Revenue: Q3 revenue stood at $33.1m / EBITDA 2.0 12.1 16.2 (88%) ₹2,903m, a decline of 26% YoY, impacted by delayed semaglutide approvals in Canada EBITDA m
Slide 9: Steady progress towards delivering our FY28 outlook
We are making steady and continuous progress towards delivering our FY28 outlook Revenue ($m) EBITDA EBITDA margin % 500+ Secular tailwinds continue to favour CDMO sector & OneSource offerings… • Rising global demand for GLP-1s; semaglutide losing patent protection in 130+ countries in Jan-Mar 2026
Slide 10: Business & Operational Updates
Business & Operational Updates Q3FY26
Slide 11: Driving strong business outcomes and scaling organisational capabilities
Driving strong business outcomes and scaling organisational capabilities Business update Organisation update • Signed 20 new MSAs and licensing deals this year; 2/3rd as repeat • Capacity expansion projects on schedule; 3/4th of $100m of business from existing customers announced capex committed • O
Slide 12: Advancing in biologics with industry tailwinds and growing customer funnel
Advancing in biologics with industry tailwinds and high-value growing customer funnel Biologics funnel Industry tailwinds • USFDA easing biosimilar development pathways to lower costs and shorten timelines, creating new opportunities for agile biologics CDMOs • FY26 NDAA bill with BIOSECURE Act elem
Slide 13: Advancing our ESG journey with measurable improvements
Advancing our ESG journey with measurable improvements EcoVadis score improved across all categories Other sustainability highlights • Became a signatory to United Nations Global Compact • Maintained CDP score of B consecutively for two years, demonstrating our FY25 Score: 64/100 7 points vs FY24 co
Slide 14: Q3FY26 earnings call details
Q3FY26 Jan Day: Saturday 24 Schedule: Date: 24th January 2026 Time: 09:30 AM IST Arun Kumar, Founder & Non-Executive Chairperson Speakers: Neeraj Sharma, CEO & MD Anurag Bhagania, CFO +91 22 6280 1372 Dial In: +91 22 7115 8193 Diamond Pass: Click here for early registration
Slide 15: OneSource at a glance
OneSource at a glance
Slide 16: Building a pure-play CDMO platform with extensive capabilities
Building a pure-play CDMO platform, distinguished by extensive capabilities and robust financial metrics ROBUST MANUFACTURING & PRESENCE ACROSS HIGHLY ATTRACTIVE EXPERT PROFESSIONALS AND ONE-OF-ITS-KIND COMPLIANCE TRACK RECORD MODALITIES INCLUDING GLP-1 FINANCIAL PROFILE SEASONED BOARD #1 5 Multiple
Slide 17: Industry-leading capacities backed by stellar compliance record
Industry-leading capacities backed by stellar compliance record Drug-device combinations Biologics development centre Sterile Injectables Soft gelatin capsules1 Penicillin fill-finish Integrated Biologics and Drug Products site Area (Sq ft) 450,000 100,000 70,000 60,000 42,000 Microbial: 1x1KL SS Ca
Slide 18: Get in touch with us
Get in touch with us REGISTERED AND CORPORATE OFFICE INVESTOR RELATIONS OneSource Specialty Pharma Ltd Investor-relations@onesourcecdmo.com Investor-relations@onesourcecdmo.com Registered Office: Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane, Maharashtra, I